ORCHARD

A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Histologically or cytologically confirmed adenocarcinoma of the lung (patients with mixed histology are eligible if adenocarcinoma is the predominant histology) harbouring EGFR mutation(s) known to be associated with EGFR TKI sensitivity at diagnosis.

Received only 1 line of therapy, with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion.

WHO 0-1

Patients whose disease has progressed within the first 3 months of osimertinib treatment (refractory to osimertinib treatment).

Patients should not have discontinued osimertinib >60 days prior to the first dose of study treatment.